V7B Stock Overview
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Assembly Biosciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$11.70 |
52 Week High | US$14.45 |
52 Week Low | US$7.51 |
Beta | 0.61 |
1 Month Change | -1.85% |
3 Month Change | 8.57% |
1 Year Change | n/a |
3 Year Change | -70.63% |
5 Year Change | -93.08% |
Change since IPO | -83.76% |
Recent News & Updates
Recent updates
Shareholder Returns
V7B | DE Biotechs | DE Market | |
---|---|---|---|
7D | -4.1% | 0.8% | -0.5% |
1Y | n/a | -21.0% | 2.5% |
Return vs Industry: Insufficient data to determine how V7B performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how V7B performed against the German Market.
Price Volatility
V7B volatility | |
---|---|
V7B Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.3% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: V7B has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine V7B's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 65 | Jason Okazaki | www.assemblybio.com |
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases in the United States. It develops ABI-5366 and ABI-1179, which is in Phase 1a/1b clinical trial targeting recurrent genital herpes; and ABI-6250, an oral hepatitis delta virus entry inhibitor that is in Phase 1a clinical studies. The company also offers ABI-4334, a next-generation capsid assembly modulator which is in Phase 1b clinical trials, for the treatment of hepatitis B virus.
Assembly Biosciences, Inc. Fundamentals Summary
V7B fundamental statistics | |
---|---|
Market cap | €67.97m |
Earnings (TTM) | -€57.20m |
Revenue (TTM) | €6.69m |
9.8x
P/S Ratio-1.1x
P/E RatioIs V7B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
V7B income statement (TTM) | |
---|---|
Revenue | US$7.16m |
Cost of Revenue | US$2.12m |
Gross Profit | US$5.05m |
Other Expenses | US$66.28m |
Earnings | -US$61.23m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -11.17 |
Gross Margin | 70.46% |
Net Profit Margin | -854.78% |
Debt/Equity Ratio | 0% |
How did V7B perform over the long term?
See historical performance and comparison